Annexon, Inc.: BIOTECHNOLOGY VALUE FUND L P amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Biotechnology Value Fund L.P. amended its Schedule 13G filing on Annexon, Inc., updating its beneficial ownership stake with the SEC under accession number 0000921895-26-003167. The filing, submitted via SEC filer ID 0000921895, reflects a change in the fund's position in the clinical-stage biopharmaceutical company. Schedule 13G amendments are typically filed by passive investors holding more than 5% of a class of securities, signaling shifts in institutional ownership. Investors will watch for further 13G or 13D filings to gauge whether Biotechnology Value Fund's position continues to evolve.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Annexon, Inc., BIOTECHNOLOGY VALUE FUND L P